Terms: = Breast cancer AND Neurokinin
88 results:
1. Harnessing the synergistic potential of NK1R antagonists and selective COX-2 inhibitors for simultaneous targeting of TNBC cells and cancer stem cells.
Singh MT; Thaggikuppe Krishnamurthy P; Magham SV
J Drug Target; 2024 Dec; 32(3):258-269. PubMed ID: 38252517
[TBL] [Abstract] [Full Text] [Related]
2. Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms.
Sassarini J; Anderson RA
Expert Opin Investig Drugs; 2024 Jan; 33(1):19-26. PubMed ID: 38224099
[TBL] [Abstract] [Full Text] [Related]
3. Impose of KNDy/GnRH neural circuit in PCOS, ageing, cancer and Alzheimer's disease: StAR actions in prevention of neuroendocrine dysfunction.
Panda SP; Kesharwani A; Singh GD; Prasanth D; Vatchavai BR; Kumari PVK; Panda SK; Mallick SP
Ageing Res Rev; 2023 Dec; 92():102086. PubMed ID: 37821047
[TBL] [Abstract] [Full Text] [Related]
4. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
[TBL] [Abstract] [Full Text] [Related]
5. Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase.
Inui N; Toi Y; Yoneshima Y; Morise M; Hata A; Kubota K; Saeki T; Tamura T
Adv Ther; 2023 Nov; 40(11):4928-4944. PubMed ID: 37715851
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
[TBL] [Abstract] [Full Text] [Related]
7. New advances in menopause symptom management.
Koysombat K; McGown P; Nyunt S; Abbara A; Dhillo WS
Best Pract Res Clin Endocrinol Metab; 2024 Jan; 38(1):101774. PubMed ID: 37076317
[TBL] [Abstract] [Full Text] [Related]
8. Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective.
Abe M; Iihara H; Aogi K
Adv Ther; 2023 May; 40(5):1913-1925. PubMed ID: 36884027
[TBL] [Abstract] [Full Text] [Related]
9. Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival.
Al-Keilani MS; Bdeir R; Elstaty RI; Alqudah MA
BMC Cancer; 2023 Feb; 23(1):158. PubMed ID: 36797689
[TBL] [Abstract] [Full Text] [Related]
10. neurokinin-1 receptor is highly expressed in cervical cancer and its antagonist induces cervical cancer cell apoptosis.
Guan L; Yuan S; Ma J; Liu H; Huang L; Zhang F
Eur J Histochem; 2023 Jan; 67(1):. PubMed ID: 36629320
[TBL] [Abstract] [Full Text] [Related]
11. Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity.
Kabil MF; Mahmoud MY; Bakr AF; Zaafar D; El-Sherbiny IM
Life Sci; 2022 Sep; 305():120731. PubMed ID: 35753435
[TBL] [Abstract] [Full Text] [Related]
12. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).
Ozeki R; Iihara H; Shimokawa M; Hashimoto H; Abe M; Mukohara T; Bando H; Hayashi T; Kawazoe H; Komoda M; Yanai Takahashi T; Saito M
BMJ Open; 2022 Mar; 12(3):e058755. PubMed ID: 35236735
[TBL] [Abstract] [Full Text] [Related]
13. Impact of the Oncology Care Model on Use of Supportive Care Medications During cancer Treatment.
Brooks GA; Landrum MB; Kapadia NS; Liu PH; Wolf R; Riedel LE; Hsu VD; Jhatakia Parekh S; Simon C; Hassol A; Keating NL
J Clin Oncol; 2022 Jun; 40(16):1763-1771. PubMed ID: 35213212
[TBL] [Abstract] [Full Text] [Related]
14. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC.
Matsuura K; Tsurutani J; Inoue K; Tanabe Y; Taira T; Kubota K; Tamura T; Saeki T
Cancer; 2022 Apr; 128(8):1692-1698. PubMed ID: 35045185
[TBL] [Abstract] [Full Text] [Related]
15. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
Hata A; Okamoto I; Inui N; Okada M; Morise M; Akiyoshi K; Takeda M; Watanabe Y; Sugawara S; Shinagawa N; Kubota K; Saeki T; Tamura T
J Clin Oncol; 2022 Jan; 40(2):180-188. PubMed ID: 34793245
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic Significance of Substance P/neurokinin 1 Receptor and Its Association with Hormonal Receptors in breast Carcinoma.
Mehboob R; Gilani SA; Hassan A; Sadaf ; Tanvir I; Javaid S; Khalid S; Hasan S; Waseem H; Alwazzan A; Munoz M
Biomed Res Int; 2021; 2021():5577820. PubMed ID: 34692834
[TBL] [Abstract] [Full Text] [Related]
17. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract] [Full Text] [Related]
18. Fatigue, Stress, and Functional Status are Associated With Taste Changes in Oncology Patients Receiving Chemotherapy.
Joseph PV; Nolden A; Kober KM; Paul SM; Cooper BA; Conley YP; Hammer MJ; Wright F; Levine JD; Miaskowski C
J Pain Symptom Manage; 2021 Aug; 62(2):373-382.e2. PubMed ID: 33259906
[TBL] [Abstract] [Full Text] [Related]
19. neurokinin 3 receptor antagonists - prime time?
Prague JK
Climacteric; 2021 Feb; 24(1):25-31. PubMed ID: 33135940
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy.
Tsuji D; Matsumoto M; Kawasaki Y; Kim YL; Yamamoto K; Nakamichi H; Sahara Y; Makuta R; Yokoi M; Miyagi T; Itoh K
Cancer Chemother Pharmacol; 2021 Jan; 87(1):73-83. PubMed ID: 33099677
[TBL] [Abstract] [Full Text] [Related]
[Next]
